Drug Discovery World

MARCH 26, 2024

It is approved in adults and adolescents (12 years of age and older weighing at least 40kg) who are moderate-to-severely immune compromised due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to Covid-19 vaccination.

FDA Approval 130

FDA Approval FDA Clinical Trials Immune Response 130

Drug Target Review

JANUARY 15, 2024

Research 1 has shown that neutrophil elastase selectively and potently kills cancer cells irrespective of their genetics and anatomical origin, mobilises adaptive immunity, and avoids resistance mechanisms. Could you provide insights into the driving factors behind exploring novel treatments for cancer types?

Treatment 105

Treatment Immune Response Clinical Trials Therapies 105

Drug Discovery World

MAY 28, 2024

Professor Trent Woodruff from UQ’s School of Biomedical Sciences said the new approach addressed an underlying cause of organ failure, while previous unsuccessful attempts had focused largely on the immune response.

Immune Response 147

Immune Response Hospitals Drugs Clinical Trials 147

Drug Discovery World

FEBRUARY 24, 2023

AELIX Therapeutics has announced positive results from its randomised, placebo-controlled Phase IIa therapeutic HIV vaccine and immune modulator combination clinical trial. The HTI vaccine is aimed at refocusing the immune response to especially vulnerable sites in HIV.

Immune Response 130

Immune Response Vaccine Trials Clinical Trials 130

Drug Discovery World

JULY 26, 2023

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. Currently, all antibodies approved for the treatment of cancer belong to a class known as IgG.

Clinical Trials 130

Clinical Trials Immune Response Drugs Trials 130

Olympian Clinical Research

MAY 6, 2024

The journey toward effective treatments has been long and evolving, with recent breakthroughs offering new hope to those living with this challenging condition. From Coal Tar to Biologics: A Historical Perspective The history of psoriasis treatment is as old as the condition itself, with records dating back to ancient times.

Treatment 52

Treatment Small Molecule Immune Response Clinical Research 52

Drug Discovery World

AUGUST 2, 2022

Biotechnology company Calidi Biotherapeutics has announced that a Phase I US clinical trial will use the company’s licensed oncolytic virotherapy platform NeuroNova to deliver an oncolytic adenovirus selectively to tumor sites in patients with recurrent high-grade glioma. .

Trials 130

Trials FDA Immune Response Clinical Trials 130

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.

Immune Response 52

Immune Response Vaccine Virus RNA 52

Olympian Clinical Research

NOVEMBER 30, 2023

While the journey to understand and treat this condition has been complex, recent innovations in vitiligo treatment have opened new doors, offering hope and improved outcomes for those affected. The Evolution of Vitiligo Treatments From ancient remedies to modern medicine, the treatment of vitiligo has undergone a remarkable transformation.

Treatment 52

Treatment Clinical Research Clinical Trials Immune Response 52

Drug Discovery World

MARCH 30, 2023

Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours.

Vaccine 130

Vaccine Regulations Trials Immune Response 130

The Pharma Data

DECEMBER 23, 2020

In the context of a substantial amount of COVID-19-related research and the launch of numerous clinical trials, the French government created this steering committee to prioritize and accelerate high potential clinical trials. PARIS–( BUSINESS WIRE )– Inotrem S.A., Marc Derive. www.inotrem.com.

Clinical Trials 52

Clinical Trials Trials Research Immune Response 52

Drug Discovery World

JANUARY 3, 2023

A monoclonal antibody to prevent Covid-19 in vulnerable patients, AZD3152, has entered clinical trials less than 12 months after discovery. . Hugo Fry, CEO of RQ Bio, comments: “We’re delighted that one of our discovered antibodies is now at the core of an innovative AstraZeneca investigational medicine reaching clinical trials.” .

Immune Response 130

Immune Response Clinical Trials Vaccine Licensing 130

Drug Discovery World

FEBRUARY 28, 2024

According to the American Association of Cancer Research (AACR) 2 , research-driven advances in treatments have resulted in the decline in death rates for melanoma, leukaemia, and kidney cancer. Currently, all antibodies approved for the treatment of cancer belong to a class known as IgG. Research into new cancer drugs remain strong.

Drug Development 162

Drug Development Research Clinical Trials Drugs 162

Drug Discovery World

APRIL 16, 2023

The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the Phase III KEYNOTE-966 clinical trial. The approval was based on results from the TOPAZ-1 clinical trial. months and 5.6

Clinical Trials 130

Clinical Trials Immune Response Trials Therapies 130

Drug Target Review

FEBRUARY 21, 2024

Stem cell transplants primarily help the immune response through the “graft-versus-leukaemia effect,” and we have to manage the “graft versus host effect.” This involves the use of CAR-T cell products derived from donor T cells, hence the term “off the shelf,” making it easier to standardise treatments.

Therapies 64

Therapies Treatment FDA Approval Vaccine 64

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The Companies expect interim results from this trial in the third quarter of 2021. About the Phase 1/2 clinical trial.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

Drug Target Review

MARCH 1, 2024

How significant are the results in terms of advancing TCR-T cell therapy and AMP immunotherapy for the treatment of solid tumours? Long-term protection against tumour recurrence in AMP-treated mice was associated with antigen spreading to additional tumour-associated antigens not targeted by the treatment.

Immune Response 105

Immune Response Vaccine Therapies Small Molecule 105

Drug Discovery World

NOVEMBER 8, 2022

mRNA-4157/V940 is currently being evaluated in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with high-risk melanoma in a Phase II clinical trial being conducted by Moderna. .

Vaccine 130

Vaccine Immune Response Research Laboratories Clinical Trials 130

Drug Discovery World

JULY 5, 2023

Precision oncology supports targeted therapeutic treatments by determining the specific molecular characteristics of a tumour – the molecular phenotype, as it’s called – to obtain an in depth understanding of the patient’s unique cancer and using it to specifically target the patient’s cancer on a molecular level.

Research 246

Research Immune Response Pharmaceutical Companies Treatment 246

Drug Discovery World

NOVEMBER 10, 2023

CAN-2409 in non-metastatic pancreatic cancer Candel Therapeutics reported on initial positive interim data from its Phase II clinical trial of CAN-2409 that showed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma (PDAC). The estimated overall survival rate was 71.4%

Pharmacokinetics 130

Pharmacokinetics Clinical Trials Immune Response Treatment 130

Drug Discovery World

APRIL 16, 2023

The clinical benefit was observed regardless of the tumour mutational burden (TMB) status, according to results from the Phase IIb KEYNOTE-942 clinical trial presented at the AACR Annual Meeting 2023, held April 14-19. The association between this treatment approach and TMB will be further explored in upcoming studies.

Vaccine 130

Vaccine Immune Response Medical Schools Trials 130

Drug Discovery World

OCTOBER 7, 2022

The research gives insight into the function of immune cells in patients with chemotherapy-resistant breast cancers. While chemotherapy may not kill cancer cells in these high-risk patients, immunotherapy, a type of treatment that helps the immune system to attack cancer cells, may provide a benefit. .

Research 130

Research Immune Response Bioinformatics Treatment 130

Conversations in Drug Development Trends

JUNE 21, 2024

The 2024 ASCO Annual Meeting from the American Society of Clinical Oncology is a fantastic platform for clinical researchers to discuss the latest advancements and challenges in oncology research. Check out this webinar on navigating the landscape of oncology clinical trials. Interested in hearing more insights from Matt?

Clinical Trials 64

Clinical Trials Clinical Research Immune Response Therapies 64

Drug Discovery World

FEBRUARY 6, 2023

By contrast, nearly all antibody drugs reaching the clinic today were and are discovered in static systems including “fully human” transgenic animals or cellular display systems. This has consequences for safety and efficacy. Starting from antibodies found in humans is a better strategy.

Immune Response 130

Immune Response Clinical Trials Drug Development Production 130

Drug Target Review

MAY 14, 2024

Since cancer cells are under chronic stimulation of ER stress, the polypeptides cannot activate innate immune sensors in cancer cells even upon the polypeptide treatment. How did the combination of the polypeptides with immune checkpoint inhibitors affect the antitumour responses in the mouse models?

Engineering 59

Engineering Immune Response FDA Approval DNA 59

Drug Discovery World

JULY 26, 2022

BM: Calidi Therapeutics’ current pipeline consists of oncolytic virus-based immunotherapies potentiated by allogeneic stem cells and designed to treat patients for whom few, if any, effective treatment options exist. RA: Could this type of treatment be used alongside other oncology therapies such a cell & gene therapies?

Virus 130

Virus Clinical Trials Therapies Trials 130

SugarCone Biotech

JUNE 10, 2024

Targeting 4-1BB remained of interest to the immuno-oncology field as cell culture experiments and tumor models in mice suggested that robust anti-tumor immune responses could be triggered by anti-4-1BB antibody therapies. This is the T cell type most closely associated with anti-tumor immune responses.

Immune Response 88

Immune Response Production Regulations Clinical Trials 88

Drug Discovery World

MAY 9, 2023

Fewer than 5% of oncology drugs that enter clinical trials in the US receive US FDA approval. This abysmal success rate significantly trails the overall approval rate for compounds entering human trials (about 10% of which reach commercialisation).

Drug Development 130

Drug Development Clinical Trials Animal Testing Cell Based Assays 130

Drug Discovery World

JULY 25, 2023

These include two antibodies for modulating immune responses in cancer and autoimmunity, which are being advanced through pharmaceutical partnerships with Novartis and GlaxoSmithKline. The clinical results to date in melanoma, lung cancer, head and neck cancer have been encouraging.

Immune Response 246

Immune Response Therapies Vaccine Production 246

Drug Discovery World

APRIL 20, 2023

There is a clear opportunity to repurpose some of these candidates for preventative/ prophylactic treatment for post-Covid-19 cognitive impairment. These may provide an opportunity for treatment for post-Covid-19 cognitive impairment. New therapeutics of course depend on an understanding of biological mechanisms.

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

The Pharma Data

APRIL 15, 2022

NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the Pfizer-BioNTech COVID-19 vaccine in healthy children 5 through 11 years of age. About the Phase 1/2/3 Trial in Children.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

JANUARY 25, 2021

Regeneron’s monoclonal antibody cocktail reduced medical visits for COVID-19 patients who had not been hospitalized by almost 50 percent, according to interim clinical trial results reported by researchers at the company. And safety outcomes were similar in the REGN-COV2 dose groups and the placebo group.

Immune Response 52

Immune Response Treatment Clinical Trials Hospitals 52

The Pharma Data

OCTOBER 14, 2020

a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, announced today that the U.S. APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. SAN CARLOS, Calif. ,

Treatment 40

Treatment Immune Response Clinical Trials Clinical Development 40

Advarra

JANUARY 11, 2024

The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. While mRNA usage has played several roles in clinical research , oncology researchers in particular are eager to explore the possibilities of mRNA-based cancer vaccines.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

PLOS: DNA Science

OCTOBER 12, 2023

Gene therapy clearly hasn’t had a major impact on health care, offering extremely expensive treatments for a few individuals with rare diseases. Can they deliver healing genes without triggering an overactive immune response? Jesse was 19, and had a disorder of the urea cycle (ornithine transcarbamylase deficiency).

Therapies 69

Therapies Immune Response DNA Virus 69

The Pharma Data

JANUARY 3, 2021

Anecdotal feedback from Foralumab-treated patients was positive and suggests that the treatment was well-tolerated. The scientific approaches underlying this clinical study could potentially be effective against SARs, MERS, and all variants of coronaviruses. NEW YORK and LONDON, Jan. .

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

The Pharma Data

MARCH 9, 2021

Ongoing Phase III studies in non-small cell lung cancer continue, evaluating canakinumab in earlier treatment settings. We sincerely thank the patients and clinical investigators involved in the CANOPY-2 study for their partnership.”. Canakinumab is a first-in-class interleukin-1beta (IL-1?) Source link:[link].

Treatment 52

Treatment Immune Response Trials Clinical Trials 52